High expression levels of PD-L1 in cancer cells and tumor-infiltrated immune cells, defined as a combined proportion score (CPS), induce more efficacy of ICIs therapy, suggesting its role as a molecular biomarker [23]. This evidence concerns the gene CD274 and neoplasm.